Calculator Guides
CKD-EPI 2021 eGFR Equation: Complete Clinical Guide
The 2021 CKD-EPI equation is now the standard for estimating GFR in adults. It removed the race variable from the 2009 equation following recognition that using race as a biological proxy introduced systematic bias. Performance is similar to the 2009 equation in most populations. eGFR <60 mL/min/1.73 m² for ≥3 months = CKD. For high-stakes decisions (drug dosing, transplant workup), confirm with cystatin C–based eGFR or measured GFR.
TL;DR: The 2021 CKD-EPI equation is now the standard for estimating GFR in adults. It removed the race variable from the 2009 equation following recognition that using race as a biological proxy introduced systematic bias. Performance is similar to the 2009 equation in most populations. eGFR <60 mL/min/1.73 m² for ≥3 months = CKD. For high-stakes decisions (drug dosing, transplant workup), confirm with cystatin C–based eGFR or measured GFR.
Table of Contents
- What Is the CKD-EPI Equation?
- Why the 2021 Update Matters
- How eGFR Is Calculated
- CKD Staging Using eGFR
- Clinical Applications
- Limitations and Considerations
- Evidence and Guidelines
- Frequently Asked Questions
- References
What Is the CKD-EPI Equation?
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation estimates glomerular filtration rate — the volume of blood the kidneys filter per minute per 1.73 m² of body surface area. Direct GFR measurement (using iohexol, inulin, or radiolabeled tracers) is accurate but expensive, slow, and invasive. eGFR from serum creatinine is a practical surrogate that clinicians use daily for CKD staging, medication dosing, and referral decisions.
The original CKD-EPI equation was published in 2009 and outperformed the older MDRD equation, particularly at eGFR values above 60 mL/min/1.73 m². The 2009 equation included a race term — specifically, a multiplier that increased estimated GFR in patients identified as Black. In 2021, the NKF and ASN task force recommended removing race from the equation.
Why the 2021 Update Matters
The race term in the 2009 equation was statistically derived from a cohort that included Black Americans who had systematically higher measured GFR for a given creatinine level. However, using race as a biological variable treats it as a fixed biological characteristic rather than a social construct.
The practical consequences were significant: Black patients were systematically assigned higher eGFR values, which delayed CKD diagnosis, slowed nephrology referral, and in some cases affected transplant listing timelines.
The 2021 equation removes race entirely. The performance tradeoff is modest — it produces lower eGFR estimates in Black patients compared to the 2009 equation, which may slightly overestimate CKD prevalence in that population, but is considered the more equitable and scientifically defensible approach.
How eGFR Is Calculated
2021 CKD-EPI Creatinine Equation (Race-Free)
eGFR = 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^(−1.200) × 0.9938^Age × [1.012 if Female]
Where:
- κ = 0.7 for females, 0.9 for males
- α = −0.241 for females, −0.302 for males
- Scr = serum creatinine in mg/dL
CKD-EPI vs MDRD
| Feature | MDRD | CKD-EPI 2009 | CKD-EPI 2021 |
|---|---|---|---|
| Year | 1999 | 2009 | 2021 |
| Race variable | Yes | Yes | No |
| Performance at eGFR >60 | Poor | Good | Good |
| Current recommendation | Deprecated | Transitioning | Preferred |
CKD Staging Using eGFR
| Stage | eGFR (mL/min/1.73 m²) | Description |
|---|---|---|
| G1 | ≥90 | Normal or high |
| G2 | 60–89 | Mildly decreased |
| G3a | 45–59 | Mildly to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | <15 | Kidney failure |
CKD diagnosis requires eGFR <60 OR kidney damage markers present for ≥3 months.
Clinical Applications
Nephrology Referral Thresholds
KDIGO recommends nephrology referral at eGFR <30 mL/min/1.73 m². Earlier referral at G3b is appropriate when CKD is progressive.
Medication Dosing
| Drug | eGFR Threshold | Action |
|---|---|---|
| Metformin | <30 | Contraindicated |
| DOACs | Varies | Reduce dose at G3b-G4 |
| SGLT2 inhibitors | <20–25 | Contraindicate |
| NSAIDs | <30 | Avoid |
Limitations and Considerations
Creatinine is influenced by muscle mass. eGFR systematically underestimates GFR in low muscle mass patients and overestimates it in highly muscular individuals.
Creatinine fluctuates in AKI. eGFR is only valid in steady-state conditions.
Cystatin C–based eGFR is more accurate in borderline cases. KDIGO now recommends confirmatory cystatin C testing when eGFR-based decisions have major clinical implications.
Evidence and Guidelines
Delanaye P et al. (2023) found both 2009 and 2021 CKD-EPI equations overestimate GFR in patients aged 18–30. The EKFC equation performed better across diverse European cohorts. Clin Kidney J. 2023;16(9):1375–1383. PMID: 37664574.
Hundemer GL et al. (2022) validated the 2021 equations in 415 kidney transplant recipients with no clinically significant differences. Am J Kidney Dis. 2022;80(4):462–472.e1. PMID: 35588905.
Frequently Asked Questions
Q: Should my lab still report eGFR with the race variable? No. As of 2022, the NKF and ASN recommended transitioning to the 2021 race-free equation.
Q: When should I use cystatin C? When muscle mass is abnormal, when eGFR is near a clinical decision threshold, or when results seem discordant with clinical status.
Q: Is MDRD still used? MDRD is deprecated in most guidelines. The 2021 CKD-EPI equation should replace MDRD in all settings.
References
- Delanaye P et al. Clin Kidney J. 2023;16(9):1375–1383. PMID: 37664574.
- Hundemer GL et al. Am J Kidney Dis. 2022;80(4):462–472.e1. PMID: 35588905.
- Inker LA et al. N Engl J Med. 2021;385(19):1737–1749. PMID: 34554658.
- KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline. Kidney Int Suppl. 2024.